EU-GMP Certification Renewed for Unit II Facility

Regulatory product approvalBusiness Updates View source PDF Explain this filing

ONESOURCE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.3%Reaction day

₹1540.00

prior close

₹1540.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-0.4%+0.7% vs market

Pharmaceuticals peers, median of 156sector-0.9%+1.3% vs sector

On the reaction day the stock moved 0.7 pts more than Nifty Smallcap 250 and 1.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.8

10m

-0.2

15m

-0.6

30m

-0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.3-0.4+0.7-0.9+1.3

Next day

+1.6+0.4+1.2-0.7+2.4

+4.2+1.5+2.7-0.2+4.4

+15.9+0.9+15.0+0.0+15.9

+15.1-0.1+15.3-1.2+16.3

+18.3+1.7+16.6+0.0+18.3

+14.3+2.2+12.1-0.1+14.3

15d

+18.8+1.8+17.0+1.7+17.1

+21.7+1.5+20.2+2.3+19.4

+4.9+8.6-3.7+6.4-1.5

+9.4+9.6-0.2+12.2-2.8

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

OneSource Specialty Pharma has received the renewal of its European Union Good Manufacturing Practices (EU-GMP) certification for its flagship Unit II manufacturing facility in Bengaluru. The certification was granted after an inspection by a European regulatory authority. Unit II is an integrated biologics drug-substance and drug-product manufacturing site with capabilities in drug-device combinations and sterile injectable products. The renewal allows the company to continue manufacturing and supplying products for the European market.

Likely market impact

Positive — EU-GMP renewal enables continued manufacturing and exports to European markets, supporting existing and new business opportunities.